Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Medical's Trifecta

This article was originally published in The Gray Sheet

Executive Summary

Firm enters the pericardial aortic stented tissue heart valve market with the European debut of Trifecta. St. Jude announced receipt of CE mark clearance for the device March 2. The device's design incorporates a titanium stent as a frame to support the valve leaflets, which are made of pericardial tissue. The "next-generation" tri-leaflet valve "has been specifically designed for improved hemodynamics, durability and implantability," the firm states. The new offering builds on St. Jude's existing valve portfolio, which includes mechanical and porcine tissue valves as well as valve annuloplasty rings
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel